Exelixis Inc Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Exelixis Inc (EXEL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 51.00 thousand shares for the 12-month period ending 2020-01-03, per its 10-K filed 2020-02-25.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2020-02-25
- Exelixis Inc share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2020-01-03 was 15.96K shares, a 27.30% increase year-over-year.
- Exelixis Inc share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2019-09-27 was 5.77K shares.
- Exelixis Inc share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2019-06-28 was 6.35K shares.
- Exelixis Inc share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2019-03-29 was 22.93K shares.
- Exelixis Inc share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2020 was 51.00K shares, a 182.06% increase from fiscal 2018.
- Exelixis Inc share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2018 was 18.08K shares, a 93.00% decline from fiscal 2017.
- Exelixis Inc share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2017 was 258.33K shares, a 220.85% increase from fiscal 2016.
- Exelixis Inc share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2016 was 80.52K shares, a 98.66% decline from fiscal 2015.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2020-01-03 | 15.96K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | 21.72K shares derived: sum of 2 quarters · filed 2020-02-25 | 28.07K shares derived: sum of 3 quarters · filed 2020-02-25 | 51.00K shares 10-K · filed 2020-02-25 |
| 2019-09-27 | 5.77K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | 12.12K shares derived: sum of 2 quarters · filed 2019-10-30 | 35.05K shares 10-Q · filed 2019-10-30 | 47.58K shares derived: sum of 4 quarters · filed 2019-10-30 |
| 2019-06-28 | 6.35K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | 29.28K shares 10-Q · filed 2019-07-31 | 41.81K shares derived: sum of 3 quarters · filed 2019-07-31 | |
| 2019-03-29 | 22.93K shares 10-Q · filed 2019-05-01 | 35.46K shares derived: sum of 2 quarters · filed 2019-05-01 | ||
| 2018-12-28 | 12.53K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | 18.08K shares 10-K · filed 2019-02-22 | ||
| 2018-09-28 | 5.55K shares 10-Q · filed 2018-11-01 | |||
| 2017-12-29 | 258.33K shares 10-K · filed 2018-02-26 | |||
| 2016-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | 0.00 shares derived: sum of 2 quarters · filed 2017-02-27 | 80.52K shares 10-K · filed 2017-02-27 | |
| 2016-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | 80.52K shares 10-Q · filed 2016-11-03 | ||
| 2016-06-30 | 80.52K shares 10-Q · filed 2016-08-03 | |||
| 2015-12-31 | 1.61M shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | 2.32M shares derived: sum of 2 quarters · filed 2016-02-29 | 2.86M shares derived: sum of 3 quarters · filed 2016-02-29 | 6.02M shares 10-K · filed 2016-02-29 |
| 2015-09-30 | 711.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | 1.25M shares derived: sum of 2 quarters · filed 2015-11-10 | 4.40M shares 10-Q · filed 2015-11-10 | 5.27M shares derived: sum of 4 quarters · filed 2015-11-10 |
| 2015-06-30 | 538.78K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | 3.69M shares 10-Q · filed 2015-08-11 | 4.56M shares derived: sum of 3 quarters · filed 2015-08-11 | 4.81M shares derived: sum of 4 quarters · filed 2015-08-11 |
| 2015-03-31 | 3.15M shares 10-Q · filed 2015-04-30 | 4.02M shares derived: sum of 2 quarters · filed 2015-04-30 | 4.27M shares derived: sum of 3 quarters · filed 2015-04-30 | 4.34M shares derived: sum of 4 quarters · filed 2015-04-30 |
| 2014-12-31 | 870.44K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | 1.12M shares derived: sum of 2 quarters · filed 2015-03-02 | 1.19M shares derived: sum of 3 quarters · filed 2015-03-02 | 1.54M shares 10-K · filed 2015-03-02 |
| 2014-09-30 | 246.31K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | 317.44K shares derived: sum of 2 quarters · filed 2014-11-04 | 669.78K shares 10-Q · filed 2014-11-04 | |
| 2014-06-30 | 71.13K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | 423.47K shares 10-Q · filed 2014-07-31 | ||
| 2014-03-31 | 352.34K shares 10-Q · filed 2014-05-01 | |||
| 2013-12-31 | 1.07M shares 10-K · filed 2015-03-02 | |||
| 2012-12-31 | 1.89M shares 10-K · filed 2015-03-02 | |||
| 2011-12-31 | 1.56M shares 10-K · filed 2014-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |